Net Income

A KIST-led delegation of Korean quantum startups partners with IBM, signaling a major push to commercialize deep tech on the global stage.

Despite strong earnings, LifeStance shares fall after a major investor sale. The company's own share repurchase signals a complex financial strategy.

Stroke recovery innovator Mobia Medical raised $150M in its IPO, but its stock stumbled on its first day, signaling a challenging road for its novel device.

The firm reported a 3.7% drop in net asset value and a net loss for Q1 2026, raising questions about its dividend sustainability despite a stable payout.

TSLX prices a $300M bond offering and plans a strategic swap to manage risk, signaling confidence and enhancing its firepower in private credit.

TCI's Q1 net income fell to just $0.2M from $4.6M a year ago, hit by rising costs and the absence of a major one-time gain from 2025.

Barings BDC maintained its dividend, but a dip in income and net asset value reveals underlying challenges in a volatile market for private credit.

The gas and convenience retailer's massive dividend hike follows a stellar quarter, showcasing financial strength in a shifting market.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

The service commerce platform saw net income jump over 700% despite a drop in adjusted EBITDA, signaling a massive strategic bet on its AI-driven future.

The media giant posted strong Q3 results, driven by a bold strategy to monetize its content with AI partners while aggressively suing content scrapers.

Amidst a 20% workforce cut, Geospace Technologies reports wider losses, testing its high-stakes strategy to pivot from oil & gas to new tech markets.

The institutional crypto exchange is filing for CFTC licenses, a move that could unlock institutional capital and reshape the US digital asset market.

As complex new global AI and data laws take effect, Canadian businesses are scrambling for guidance, fueling a boom in specialized advisory services.

Despite a Q1 net loss, Mach Natural Resources boosts its cash distribution and shifts capital to oil, signaling confidence in its operational strength.

The LGBTQ+ app reports record Q1 earnings and plans a premium 'Edge' service, but faces growing challenges with data privacy and anti-gay policies.

The chipmaker topped Q1 estimates and eyes a strong Q2, fueled by EV and AI markets, even as restructuring charges weigh on its bottom line.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

The private energy giant posted $171M in free cash flow, cut debt, and earned a Fitch upgrade, signaling robust health amid market volatility.